181: Patient Experience Survey of Early-Stage Breast Cancer Patients Undergoing Whole Breast Radiotherapy  by Lee, Grace et al.
S66                                                                                     CARO 2016 
_________________________________________________________________________________________________________ 
Purpose: Develop an evidence-based decision-support 
framework for optimizing the location of Radium 223 (Ra) 
treatment facilities based on different metrics of geographic 
access. 
Methods and Materials: Residence at death and death date for 
all patients who died of prostate cancer in British Columbia 
between 2009 and 2014 were obtained from a prospectively 
maintained population-based registry. Patients who died of 
prostate cancer were considered potentially eligible for Ra 
treatment prior to death, assuming that they would go through 
a phase of symptoms from bone metastases. Forty-percent of 
patients in the province are known to receive palliative 
radiotherapy to bone prior to death from prostate cancer. Two 
metrics of geographic access were defined: average travel time 
to a treatment facility (ATT) and percentage of patients residing 
within 90 minutes travel to a treatment facility (C90). At the 
time of analysis, three nuclear medicine facilities were providing 
Ra (Vancouver, Victoria and Kelowna). All 22 other licensed 
nuclear medical facilities in the province were considered as 
feasible new locations for Ra treatment. Travel time from each 
patient’s residence to every facility was calculated using 
Microsoft MapPoint. An integer programming model was 
developed to find the facility locations that optimize ATT and 
C90. C90 was considered primary metric as ATT tends to 
overweight a small number of cases with very long travel times. 
Results: 3194 patients met eligibility criteria. Several scenarios 
seeking to improve geographic access by choosing different 
locations for Ra treatment were run. The first group of scenarios 
considered the existing locations and tested the addition of new 
locations from the nuclear medical facilities. Prior to death, 67% 
of patients lived within 90 minutes of one of the three centres 
currently providing Ra. C90 increased to 75%, 79%, and 82% when 
one, two and three additional facilities were added. ATT 
decreased from 156 minutes to 89, 79 and 70 minutes 
respectively. The additional facilities (mid-Vancouver Island, 
Kamloops and eastern Fraser Valley successively) were in areas 
with medium-high population density and long distances to the 
existing Ra facilities. To reach a C90 of 90%, a total of seven 
additional facilities would have to be opened. A second group of 
scenarios assumed a “greenfield” setting with no pre-existing 
facilities. Resulting facility locations differed from the existing 
locations and improved C90 to 70%, 78%, 82% and 85% with three, 
four, five and six Ra treatment facilities. 
Conclusions: Geographic access is one of the important factors 
to consider when deciding the location of treatment facilities. 
By measuring geographic access and determining optimal 
location of new facilities, the proposed framework provides a 
data-driven approach to quantitatively evaluate the 
configuration of a treatment delivery system. This framework 
can be expanded to include other clinical, operational and 
political considerations. 
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Purpose:  With increasing incidence and prevalence of cancer in 
Canada and beyond, the use of radiation therapy (RT) for both 
curative and palliative intents will continue to increase. 
Combined with the unprecedented pace of technological 
innovation and increasing complexity of care, the RT system 
must find new models of care to rethink the distribution of work 
and the skill sets required to do this work. In Ontario, the Clinical 
Specialist Radiation Therapy (CSRT) Project was created to 
ascertain if advanced practice radiation therapists (APRT) could 
add effectiveness and efficiency to the already burdened system 
in a value-added way. Since 2004, the project team has 
developed, implemented and evaluated the APRT role in a 
variety of clinical settings. 
Methods and Materials: After a period of time allotted to allow 
the pilot APRTs to acquire and prove competence in activities 
specific to their particular positions, mixed methods were used 
to test the impact of redistributing workload between APRTs and 
radiation oncologists (RO) under the headings of: 1) Quantity - 
ability to increase capacity at point of entry to the system 
(direct) and within the care pathway (indirect); 2) Quality - 
improvement in provision of patient care or addition of new 
services to improve the patient experience and/or satisfaction; 
and 3) Innovation and Knowledge Translation – the volume of 
research and innovation activities that include or are being led 
by APRTs. 
Results: In the 2014-2015 year, there were 24 CSRT “active” 
positions in place, with 21 of them being considered permanent 
full-time (CCO, 2015). Under the heading of Quantity, many 
positive direct and indirect impacts have been reported with the 
addition of CSRTs including: an increase in the number of new 
patients seen in consult (direct) and the number of RO hours 
saved (indirect). The reported number of additional patients 
seen was as high as 28 new patients per month (33% increase; 
average: 20%) and the reported number of RO hours saved were 
as high as 50 hours per month (average: 12.5 hours) which, at its 
maximum, represents a significant amount of ROs’ time 
allocated to clinical work and patient care (CCO, 2015).  
Conclusions: The CSRT-driven model of care can provide 
significant added value to the existing RT system by adding 
capacity for an increased number of patients to enter the system 
and for ROs to focus on more complex activities in their scope. 
It is suggested that this model should be considered a viable 
option for managing the pressures of the changing landscape in 
RT in Canada. 
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Purpose: Adjuvant breast radiotherapy (RT) is a standard 
treatment option in women with early-stage breast cancer 
following lumpectomy. Timeliness of RT treatment can impact 
patient satisfaction. The objectives of this study are to assess: 
1) patient satisfaction of their whole breast RT; 2) patient
preference for timing of RT start after CT simulation (CTSim); 
and 3) factors that influence patient stress and quality of life. 
Methods and Materials: Women undergoing whole breast RT 
were given a survey before RT treatment and at treatment 
completion. Patients were offered treatment either through the 
conventional process (ConvProcess), where RT starts typically 
within 1-2 weeks of CTSim, or the QuickStart (QS) process, where 
RT starts one day after CTSim. The pre-treatment (PRE-Tx) 
survey included questions to understand the social impact of RT, 
and the post-treatment (POST-Tx) survey included questions 
relating to social climate and patient satisfaction. Questions 
relating to RT start preference, stress (Perceived Stress Scale 
[PSS]) and quality of life (Illness Intrusiveness Ratings Scale 
[IIRS]), were assessed both at PRE-Tx and POST-Tx. An analysis 
of covariance was used to determine if the RT process impacted 
PSS and IIRS, and t-tests were used as a secondary analysis. 
Fisher’s Exact test was used where appropriate. 
Results: Ninety-six patients completed the PRE-Tx survey and 88 
completed both surveys (QS process n = 28; ConvProcess n = 60). 
All patients indicated they had a positive experience with the RT 
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team (strongly agree-64%; agree-36%) and would recommend 
their care (strongly agree-75%; agree-25%). At PRE-Tx, 94% of the 
QS patients preferred to start RT within a day of CTSim compared 
to 16% of ConvProcess patients. The preference of ConvProcess 
patients changed significantly compared to QS patients at POST-
TX (p < 0.0001); 63% of ConvProcess and 96% of QS patients 
strongly agreed/agreed that given a choice they would prefer to 
start RT the next day after CTSim. The overall PSS for all patients 
were not different PRE- and POST-Tx (p = .8) and stress levels 
did not differ significantly between QS and ConvProcess patients 
(p = .76). For both groups, health was the most common stress. 
The IIRS for ConvProcess patients was 37.6 (PRE-TX) and 39 
(POST-TX), and for QS patients was 32 (PRE-TX) and 31.8 (POST-
TX); there was no difference in IIRS of ConvProcess and QS 
patients (p = .2). However, subscales of IIRS showed an increase 
in illness interference with aspects of Physical Recreation and 
Social relationships for ConvProcess patients compared to QS 
patients (p = .03). 
Conclusions: Women undergoing whole breast RT were satisfied 
with their care and preferred to start RT quickly following their 
CTSim. Their strongest stressor was health and their stress levels 
were unchanged at RT completion. Patient involvement and 
selection of RT timing may impact on their views of how 
treatment interferes with their lifestyle and social relationships. 
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Purpose:  Quality of Life (QoL) assessment in cancer clinical 
trials provides a more accurate evaluation of the well-being of 
individuals or groups of patients and of the benefits and side-
effects that may result from medical intervention. Therefore, 
our first task in dealing with cancer is to regain some sort of 
equilibrium which will include mental, physical and spiritual 
aspect of that individual by addressing these very real issues and 
creating a support system tailored to our patient and their needs.  
Methods and Materials: As part of a Dean’s summer project a 
survey was undertaken to facilitate a more complete description 
of the quality of life experience of patients with histological 
diagnosis of cancer undergoing external beam radiation as an 
outpatient at Allan Blair Cancer Centre, Regina, Canada. The 
questionnaires had two major components; depression and 
global QOL. The depression was measured by the Zung Self-
Rating Depression Scale which is a short self-administered survey 
to quantify the depression status of a patient.  
Results: That data indicated that only the variable of age was a 
significant predictor. A positive relationship was present 
indicating higher levels of depression when patients received 
chemotherapy or narcotics. Breast cancer patients rated quality 
of life, functional well-being significantly higher than lung 
cancer patients p > 0.05.Breast cancer patients also scored 
significantly lower on the measure of depression than lung cancer 
patients p > 0 .05.  
Conclusions: A significant relationship between the 
chemotherapy, narcotics use and QOL was found in our study. 
For clinicians, this means not only demonstrating that such data 
are clinically useful but also addressing the effect on clinic work 
flow, constrained resources for data collection and management, 
reimbursement for their time and effort in monitoring health 
related QoL. 
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Purpose: Respiratory motion management is used in breast 
radiotherapy to reduce dose to cardiac and pulmonary organs at 
risk or decrease required margins. Varian Real-time Position 
Management (RPM) is a common tool for gated and Deep 
Inspiration Breath Hold (DIBH) treatments in breast. The external 
marker block is typically placed between the xiphoid process and 
the umbilicus. However, block movement in this location may 
not be well correlated with the internal chest wall motion. Here, 
we examine the feasibility of placing the marker block directly 
on the breast/chest wall to improve the correlation between the 
target and external marker motion. 
Methods and Materials: Three primary concerns are considered: 
1) the bolusing effect of placing the marker block in the primary 
field; 2) amplitude accuracy with block positioning; and 3) 
correlation between the exterior surface position and internal 
motion.1) We determine the bolusing effect of the two-dot, six-
dot, and ‘hippo’ (TrueBeam) marker blocks for a 6 MV beam at 
perpendicular incidence (Gantry 0°) using a Markus ionization 
chamber. 2) When the marker block is placed on an intact breast, 
it may tilt in the lateral direction. We investigate the impact of 
tilt (0° to 50°) on detected motion amplitude of the two-dot and 
six-dot marker block systems. 3) An in-house edge detection code 
was used to extract internal chest wall and external surface 
contours on each frame of weekly during-treatment cine portal 
images on the medial field from 20 DIBH patients. A population-
based correlation study determines the external surface block 
location that best represents internal chest wall motion. 
Results: 1) At perpendicular beam incidence, all three marker 
blocks doubled the surface dose reading compared to the surface 
dose with no marker block. This is equivalent to approximately 
2.5 mm of bolus. Increasing beam obliquity is expected to 
increase this bolusing effect. 2) The RPM system overestimated 
the detected amplitude of the two-dot marker block when the 
block was tilted laterally: on average by 1 mm at 20°; 2.5 mm at 
30°; 5 mm at 40°; and 8 mm at 50°. The detected amplitude 
when using the six-dot marker block system was unaffected by 
lateral tilt. 3) Preliminary results using the cine portal image 
chest wall and surface contours suggest that positioning the 
marker block at the nipple line best represents central chest wall 
motion. 
Conclusions: Placing the RPM marker block on the breast/chest 
wall at the nipple line is expected to improve the correlation 
between the block movement and chest wall motion with a small 
impact on skin dose. The six-dot marker block system should be 
used for intact breast, as it is more robust to lateral tilting than 
the two-dot marker block system. A study of 24 left-sided breast 
patients using this block placement for DIBH treatments is 
currently underway at our centre. 
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Purpose: Amongst uncommon primary ocular tumours, choroidal 
melanoma represents the most common diagnosis. Our preferred 
treatment for juxtapapillary tumours has been stereotactic 
radiotherapy using the Cyberknife radiosurgery system. We aim 
to describe our immobilization system and quantify its 
reproducibility. 
Methods and Materials: Patients treated for choroidal melanoma 
were identified in our radiosurgery database. Patients were 
imaged at CT simulator with an in-house system which allows 
visual monitoring of the eye as the patient fixates a small target. 
All patients were re-imaged at least once prior to and/or during 
radiotherapy. The patients were treated on the Cyberknife 
system, 60 Gy in 10 daily fractions, using skull tracking in 
conjunction with our visual monitoring system. In order to 
